Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer.

Savannah S Liddell,Sakti Chakrabarti,Grant A Wintheiser,Tyler J Zemla,Qian Shi,Sri Harsha Tella,Zhaohui Jin,Vanessa B Wookey,Hind Hassan,Nguyen H Tran,Mitesh J Borad,Amit Mahipal

JCO precision oncology（2022）

引用 4|浏览3

暂无评分

摘要

ICIs are well tolerated and have modest antitumor activity in patients with advanced BTC. The study result supports the exploration of tumor mutational burden as a potential predictive biomarker for response to ICIs in patients with advanced BTC.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要